Targeted radionuclide therapy holds significant potentials in cancer treatment by delivering high cytotoxic doses of ionizing radiation to cancer cells,while minimizing damage to surrounding tissues.Compared to β nuclides,α nuclides have a shorter range and more focused energy deposition.While effectively causing DNA double-strand breaks to kill cancer cells thoroughly,it also presents fewer radiation-related issues.Among α nuclides,Astatine-211(211 At)has emerged as one of the most promising candidates for targeted α-therapy due to its advantages such as low cost and availability of raw materials,low off-target toxicity of daughter radionuclides,and a short half-life.Various carriers,including monoclonal antibodies,small molecules,peptides,polypeptides,and nanoparticles,have been developed to deliver 211At into target cells.This paper reviews the current state and recent progress of clinical and pre-clinical studies on 211At-labeled targeted drugs based on different carriers.
关键词
α核素靶向治疗/放射性核素药物/211/At
Key words
Targeted alpha therapy/Radiopharmaceuticals/211 At
维普
万方数据